Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimates
Glaukos (GKOS) came out with a quarterly loss of $0.52 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.55 per share a year ago.
Glaukos (GKOS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Glaukos (GKOS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Glaukos (GKOS) Gains 51.9% YTD: What's Driving the Stock?
Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.
Here's Why You Should Retain Glaukos (GKOS) Stock for Now
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
Glaukos (GKOS) Reaches 52-Week High: What's Driving the Stock?
Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.
Glaukos (GKOS) Stock Jumps 3.7%: Will It Continue to Soar?
Glaukos (GKOS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Glaukos (GKOS) Gains 40.4% YTD: What's Driving the Rally?
Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.
Here's Why You Should Retain Glaukos (GKOS) Stock for Now
Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
National Bank of Canada FI Takes $46,000 Position in Glaukos Co. (NYSE:GKOS)
National Bank of Canada FI bought a new stake in Glaukos Co. (NYSE:GKOS – Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 600 shares of the medical instruments supplier’s stock, valued at approximately $46,000. Other institutional investors have also modified their holdings of the company. Commonwealth Equity Services LLC grew its position in Glaukos by 20.7% in the 3rd quarter. Commonwealth Equity Services LLC now owns 5,582 shares of the medical instruments supplier’s stock valued at $420,000 after buying an additional 959 shares during the last quarter. Raymond James & Associates boosted its position in shares of Glaukos by 18.9% during the 3rd quarter. Raymond James & Associates now owns 12,898 shares of the medical instruments supplier’s stock worth $971,000 after purchasing an additional 2,053 shares in the last quarter. Strs Ohio boosted its position in shares of Glaukos by 45.8% during the 3rd quarter. Strs Ohio now owns 3,500 shares of the medical instruments supplier’s stock worth $263,000 after purchasing an additional 1,100 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Glaukos by 5.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 23,932 shares of the medical instruments supplier’s stock worth $1,801,000 after purchasing an additional 1,222 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its position in shares of Glaukos by 17.3% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,827 shares of the medical instruments supplier’s stock worth $137,000 after purchasing an additional 270 shares in the last quarter. 99.04% of the stock is owned by institutional investors and hedge funds. Wall Street Analysts Forecast Growth GKOS has been the topic of several recent research reports. BTIG Research boosted their price objective on shares of Glaukos from $107.00 to $112.00 and gave the stock a “buy” rating in a research report on Thursday, May 2nd. Citigroup boosted their target price on shares of Glaukos from $107.00 to $120.00 and gave the company a “buy” rating in a research note on Monday, March 25th. Mizuho boosted their target price on shares of Glaukos from $85.00 to $100.00 and gave the company a “neutral” rating in a research note on Thursday, April 11th. Truist Financial reissued a “buy” rating and issued a $125.00 target price (up previously from $120.00) on shares of Glaukos in a research note on Thursday, May 2nd. Finally, StockNews.com downgraded shares of Glaukos from a “hold” rating to a “sell” rating in a research note on Tuesday, February 27th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat, Glaukos currently has an average rating of “Moderate Buy” and a consensus target price of $108.64. Read Our Latest Stock Report on GKOS Glaukos Stock Down 0.6 % Shares of NYSE:GKOS opened at $109.79 on Monday. The stock has a market capitalization of $5.53 billion, a P/E ratio of -38.12 and a beta of 1.08. Glaukos Co. has a 1 year low of $54.38 and a 1 year high of $113.97. The stock has a 50-day simple moving average of $97.41 and a 200-day simple moving average of $85.99. The company has a debt-to-equity ratio of 0.78, a quick ratio of 4.68 and a current ratio of 5.38. Glaukos (NYSE:GKOS – Get Free Report) last released its quarterly earnings results on Wednesday, May 1st. The medical instruments supplier reported ($0.70) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.12). The company had revenue of $85.60 million during the quarter, compared to analysts’ expectations of $79.60 million. Glaukos had a negative return on equity of 24.69% and a negative net margin of 43.15%. The firm’s revenue was up 15.8% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.59) EPS. Equities analysts forecast that Glaukos Co. will post -2.26 earnings per share for the current year. Insiders Place Their Bets In other Glaukos news, Director Marc Stapley sold 6,250 shares of the company’s stock in a transaction that occurred on Wednesday, May 15th. The stock was sold at an average price of $112.80, for a total value of $705,000.00. Following the completion of the transaction, the director now owns 32,360 shares in the company, valued at approximately $3,650,208. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, Director Mark J. Foley sold 4,560 shares of the stock in a transaction that occurred on Friday, February 23rd. The stock was sold at an average price of $92.87, for a total transaction of $423,487.20. Following the completion of the transaction, the director now directly owns 33,220 shares in the company, valued at approximately $3,085,141.40. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Marc Stapley sold 6,250 shares of the stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $112.80, for a total value of $705,000.00. Following the transaction, the director now owns 32,360 shares of the company’s stock, valued at $3,650,208. The disclosure for this sale can be found here. Insiders sold a total of 238,030 shares of company stock worth $22,629,937 in the last 90 days. 6.40% of the stock is owned by company insiders. Glaukos Profile (Free Report) Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.
